AU2006334733A1 - Combination of triazine derivatives and HMG-COA reductase inhibitors for the treatment of diabetes - Google Patents

Combination of triazine derivatives and HMG-COA reductase inhibitors for the treatment of diabetes Download PDF

Info

Publication number
AU2006334733A1
AU2006334733A1 AU2006334733A AU2006334733A AU2006334733A1 AU 2006334733 A1 AU2006334733 A1 AU 2006334733A1 AU 2006334733 A AU2006334733 A AU 2006334733A AU 2006334733 A AU2006334733 A AU 2006334733A AU 2006334733 A1 AU2006334733 A1 AU 2006334733A1
Authority
AU
Australia
Prior art keywords
alkoxy
alkyl
amino
aryl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006334733A
Other languages
English (en)
Inventor
Daniel Cravo
Didier Mesangeau
Gerard Moinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of AU2006334733A1 publication Critical patent/AU2006334733A1/en
Assigned to POXEL SAS reassignment POXEL SAS Request for Assignment Assignors: MERCK PATENT GMBH
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2006334733A 2006-01-13 2006-12-18 Combination of triazine derivatives and HMG-COA reductase inhibitors for the treatment of diabetes Abandoned AU2006334733A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600343A FR2896158B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR06/00343 2006-01-13
PCT/EP2006/012184 WO2007079916A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes

Publications (1)

Publication Number Publication Date
AU2006334733A1 true AU2006334733A1 (en) 2007-07-19

Family

ID=36649749

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006334733A Abandoned AU2006334733A1 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and HMG-COA reductase inhibitors for the treatment of diabetes

Country Status (14)

Country Link
US (1) US20100158999A1 (cg-RX-API-DMAC10.html)
EP (1) EP1978951A2 (cg-RX-API-DMAC10.html)
JP (1) JP2009523141A (cg-RX-API-DMAC10.html)
KR (1) KR20080085208A (cg-RX-API-DMAC10.html)
CN (1) CN101355935A (cg-RX-API-DMAC10.html)
AR (1) AR059031A1 (cg-RX-API-DMAC10.html)
AU (1) AU2006334733A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0621420A2 (cg-RX-API-DMAC10.html)
CA (1) CA2636840A1 (cg-RX-API-DMAC10.html)
EA (1) EA200801666A1 (cg-RX-API-DMAC10.html)
FR (1) FR2896158B1 (cg-RX-API-DMAC10.html)
IL (1) IL192594A0 (cg-RX-API-DMAC10.html)
WO (1) WO2007079916A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806937B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US8722674B2 (en) 2007-08-31 2014-05-13 Hanall Biopharma Co., Ltd. 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same
JP5485292B2 (ja) * 2008-12-12 2014-05-07 ポクセル・エスアーエス Ampk活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
KR20220113942A (ko) * 2019-12-13 2022-08-17 스미토모 파마 가부시키가이샤 제조성 및 용출성이 우수한 소형 정제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin

Also Published As

Publication number Publication date
CN101355935A (zh) 2009-01-28
FR2896158B1 (fr) 2008-09-12
WO2007079916A3 (en) 2007-12-06
CA2636840A1 (en) 2007-07-19
FR2896158A1 (fr) 2007-07-20
EA200801666A1 (ru) 2008-12-30
US20100158999A1 (en) 2010-06-24
WO2007079916A2 (en) 2007-07-19
ZA200806937B (en) 2009-07-29
BRPI0621420A2 (pt) 2011-12-06
AR059031A1 (es) 2008-03-12
JP2009523141A (ja) 2009-06-18
IL192594A0 (en) 2009-09-22
KR20080085208A (ko) 2008-09-23
EP1978951A2 (en) 2008-10-15

Similar Documents

Publication Publication Date Title
TWI407955B (zh) 高脂血症之預防及/或治療劑
US20140050786A1 (en) Combination of triazine derivatives and insulin sensitisers
AU2004266070A1 (en) Pharmaceutical composition comprising a combination of metformin and a statin
US20100158999A1 (en) Combination of triazine derivatives and hmg-coa reductase inhibitors
EP1971339B1 (en) Combination of triazine derivatives and insulin secretion stimulators
MX2008008887A (en) Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes
HK1128231A (en) Combination of triazine derivatives and hmg-coa reductase inhibitors for the treatment of diabetes
AU2006334735A1 (en) Combination of triazine derivatives and PPAR&agr;agonists
HK1128233A (en) COMBINATION OF TRIAZINE DERIVATIVES AND PPARα AGONISTS
MX2008008895A (en) Combination of triazine derivatives and insulin sensitisers
HK1128232A (en) Combination of triazine derivatives and insulin sensitisers
MX2008008894A (en) Combination of triazine derivatives and insulin secretion stimulators

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: POXEL SAS

Free format text: FORMER APPLICANT(S): MERCK PATENT GMBH

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application